Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Key facts

Sponsor

Center for International Blood and Marrow Transplant Research

Principal Investigator

Eneida Nemecek, MD

Doernbecher Children's Hospital, Oregon Health & Science University

Intervention

Treosulfan(drug)

Enrollment

40 enrolled

Eligibility

21 years · All sexes

Timeline

2013 – 2015

Study locations (23)

• Children's Hospital of Alabama/UAB, Birmingham, Alabama, United States
• Phoenix Children's Hospital, Phoenix, Arizona, United States
• City of Hope, Duarte, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Children's Hospital of Colorado, Aurora, Colorado, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• All Children's Hospital, St. Petersburg, Florida, United States
• Riley Hospital for Children/Indiana University, Indianapolis, Indiana, United States
• University of Michigan, Ann Arbor, Michigan, United States
• University of Minnesota, Minneapolis, Minnesota, United States
• Children's Mercy Hospital, Kansas City, Missouri, United States
• Washington University, St. Louis Children's, St Louis, Missouri, United States
• University Hospitals Case Medical Center, Cleveland, Ohio, United States
• Cleveland Clinic, Cleveland, Ohio, United States
• Nationwide Children's Hospital, Columbus, Ohio, United States
• +8 more locations on ClinicalTrials.gov

Collaborators

National Marrow Donor Program · Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) · Pediatric Blood and Marrow Transplant Consortium · St. Baldrick's Foundation · medac GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →